Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples

PURPOSE: Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRP-R) are expressed in prostate cancer and can be targeted with radiolabeled inhibitors and antagonists. Their performances for the initial characterization of prostatic tumors have been barely evaluated but...

Descripción completa

Detalles Bibliográficos
Autores principales: Schollhammer, Romain, De Clermont Gallerande, Henri, Yacoub, Mokrane, Quintyn Ranty, Marie-Laure, Barthe, Nicole, Vimont, Delphine, Hindié, Elif, Fernandez, Philippe, Morgat, Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546761/
https://www.ncbi.nlm.nih.gov/pubmed/31161459
http://dx.doi.org/10.1186/s13550-019-0517-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546761/
https://www.ncbi.nlm.nih.gov/pubmed/31161459
http://dx.doi.org/10.1186/s13550-019-0517-6

Ejemplares similares